Alimta

... Local biotech pushing for anti-cancer drug - 2005-03-28 News by Markets bizjournals.com Albany Albuquerque Atlanta Austin Baltimore Birmingham Boston Buffalo Charlotte Cincinnati Columbus Dallas Dayton Denver East Bay Greensboro Honolulu Houston Jacksonville Kansas City Los Angeles Louisville Memphis Milwaukee Mpls./St.

Paul Nashville Orlando Philadelphia Phoenix Pittsburgh Portland Raleigh/Durham Sacramento St.

Louis San Antonio San Francisco San Jose Seattle South Florida Tampa Bay Washington Wichita News by Industry - - - - Industry Journal Home my Industry Page Email Alert - - - - Agriculture - - - - Banking & Finance -Commercial Banking -Insurance -Investing -Investment Banking -Venture Capital - - - - Business Services -Accounting/Consult.

-Advertising/PR -Employee Benefits -Environ.

Services -Human Resources -Legal Services -Marketing -Workplace Reg.

- - - - Economic View -Bankruptcies -Economic Snapshot - - - - Energy -Electric Utilities -Energy Conserv.

-Oil & Gas - - - - Health Care -Biotechnology -Health Insurance -Hospitals -Industry Regs -Pharmaceuticals -Physician Prac.

- - - - High Tech -Cable, TV & Radio -Computers -E-Commerce -Internet -Networking -Semiconductors -Software -Telecom -Wireless/PDAs - - - - Manufacturing - - - - Real Estate -Commercial -Construction -REITS & Finance -Residential - - - - Retailing & Restaurants -Restaurants -Retailing - - - - Sports Business - - - - Travel -Airlines/Airports -Lodging/Conven.

-Tourism -Travel Services bizjournals...

... W*USA 9 - Health Advertisement Home Weather Sports Live Traffic Snow Closings HDTV FAQ News Media Kit New Research Indicates Tumor Treatment Helpful With Lung Cancer Written by USA Today Created:3/15/2005 11:16:00 AM Last Updated:3/15/2005 11:34:04 AM E-mail This Story Printable Version Questions or Comments?

Avastin, a cancer therapy approved a year ago to treat colon tumors, also helps prolong life in lung cancer patients, the National Cancer Institute (NCI) announced Monday.The news is the latest of several recent advances in lung cancer, which kills nearly 164,000 a year in the USA, more than any other cancer.Avastin, made by Genentech of South San Francisco, belongs to a class of drugs called angiogenesis inhibitors.

It was the fir...

... Kalypsys Announces Key Appointments Kalypsys Announces Key Appointments -Additions Made to Board of Directors- SAN DIEGO, March 15 /PRNewswire/ - Kalypsys, a privately owned San Diego-based drug discovery and development company, announced today the appointment of Philip Needleman, PhD and August Watanabe, MD to its Board of Directors.

Dr.

Needleman brings more than 30 years of pharmaceutical experience to the Board, most recently having served as senior executive vice president of Pharmacia.

While there, he also held positions as chief scientist and chairman of research and development, overseeing the commercialization of blockbuster drugs including Celebrex(R), Bextra(R), Dynastat(R) and Inspra(R).

Prior to his work at Pharmacia, Dr.

Needleman served as president of Searle Research and Development and senior vice president and chief scientist of Monsanto.

He spent 25 years as professor and chairman of the department of pharmacology at Washington University School of Medicine and has been honored with the John Jacob Abel Award of the American Pharmacology Society, the Research Achievement Award of the American Heart Association and the Chester Stock Award of the Memorial Sloane Kettering Cancer Center.

Dr.

Needleman is a member of both the National Academy of Science and the Institute of Medicine.

Also joining the Kalypsys Board of Directors is Dr.

August Watanabe, a former senior executive at Eli Lilly Company where he served for 13 years during which...